September 19, 2019
Topics
- Nucleoside-modified mRNA-lipid nanoparticle vaccine platform for infectious diseases.
- What’s new in TB vaccine development
- VLP-based vaccine/therapeutics in the context of allergic diseases
- Specific delivery of therapeutic mRNA to different cell types and organs using targeted LNPs
- Cytomegalovirus and risk of Tuberculosis disease
Posted in Events